Stockysis Logo
  • Login
  • Register
Back to News

Organon's Supplemental Biologics License Application Gets FDA Approval For TOFIDENCE To Treat Chimeric Antigen Receptor T Cell-Induced Severe Or Life-Threatening Cytokine Release Syndrome

Benzinga Newsdesk www.benzinga.com Positive 94.4%
Neg 0% Neu 0% Pos 94.4%
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Stockysis © 2026 BISSINT LLC.
Terms of Service Contact Us